RENNOVA HEALTH ISSUES LETTER TO STOCKHOLDERS WEST PALM

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
100
RENNOVA HEALTH ISSUES LETTER TO STOCKHOLDERS

WEST PALM BEACH, FL --(Marketwired - August 28, 2017) - Rennova Health, Inc. ( NASDAQ : RNVA ) ( NASDAQ : RNVAZ ) ("Rennova" or the "Company") today announced that Seamus Lagan, chief executive officer, has issued a letter to stockholders. The text is below.

August 28, 2017

To My Fellow Stockholders:

I would like to take this opportunity to update you on our activities and progress, and to share with you some insights into our Company's direction through 2018. Importantly, by the end of 2017 we expect to have our corporate and business restructuring process complete!

On August 8, 2017, Big South Fork Medical Center, our hospital in Tennessee, opened its doors and marked the start of a new journey for Rennova, one where we will be providing needed services with less reliance on sales efforts and the associated costs. This hospital historically was profitable, with revenue of approximately $12 million in its last year of operation. To date Rennova has invested approximately $5 million in this project. Already patient visits are exceeding our expectations. We are looking to expand our hospital operations with the possible acquisition of other similar rural healthcare facilities and physician practices in adjacent areas.

The previously reported dramatic disruption in the toxicology diagnostics sector, which had been the Company's primary business focus, forced many competitors out of the market. As a result of cost cutting and consolidation, Rennova is now exceptionally well positioned to see our innovative business model, stance on compliance and focused sales efforts once again deliver growth and results.

Over the past 18 months we have faced many challenges, all of which have been surmounted with persistence and confidence. The decrease in revenue and cash generation has required us to raise capital through the sale of equity securities to meet the needs of the business. We completed two public offerings in 2016 and have raised approximately $13 million in 2017. We expect that our business will continue to secure the necessary capital to complete the turnaround and final parts of our restructuring plan.

As of June 30, 2017, our balance sheet had negative stockholders' equity of approximately $17 million, compared with negative $65 million as of March 31, 2017. This improvement is due in large part to changes in accounting practices for derivative liabilities, which are fully explained in our June 30, 2017 Form 10-Q filing with the Securities and Exchange Commission. Additionally, there were significant conversions of debt by existing debenture holders.

As we have previously informed you, as part of our plan to regain compliance with NASDAQ's stockholders' equity continued-listing requirement, in the near future Rennova intends to spin-off to its stockholders our genetic testing division, Advanced Molecular Services Group, Inc. (AMSG), and our IT and Software division, Health Technology Solutions, Inc. (HTS). To date we have invested more than $20 million in these businesses. Rennova's Board has decided to spin-off these businesses directly to our stockholders in anticipation that the market will better appreciate the focused business plan and management of each division separately, while allowing Rennova to focus on its core competencies. In addition, we expect that we will be able to recognize our investment in these businesses as equity on our balance sheet, further reducing and largely curing the net equity deficiency and meeting the stockholders' equity requirement of NASDAQ.

The opportunity for AMSG to grow pharmacogenomics testing and expand into oncology diagnostics -- combining technology and informatics to provide meaningful interpretation of results while at the same time launching a mobile app-based platform to facilitate many exciting products in this space -- is significant.

HTS has a well-established suite of software products and medical billing services that we believe can be grown from initial revenues into meaningful and profitable revenues within 12 to 18 months.

We look forward to our stockholders benefiting from improved stockholders' equity in Rennova Health and enjoying direct ownership of shares in these divisions after the spin-off. We anticipate the spin-off process for both divisions will be completed in the coming months. We are excited about the opportunity to leverage the investment and products we have developed to date, and to grow revenue in these independent companies.

I would like to personally thank the board and all our stockholders for their continued support during this transition period.

Sincerely,

Seamus Lagan

Chief Executive Officer Rennova Health, Inc.

About Rennova Health, Inc.

Rennova provides industry-leading diagnostics and supportive software solutions to healthcare providers, delivering an efficient, effective patient experience and superior clinical outcomes. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. For more information, please visit www.rennovahealth.com .

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company's most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

Contacts: Rennova Health Sebastien Sainsbury 561-666-9818 ssainsbury@rennovahealth.com Investors LHA Investor Relations Kim Golodetz 212-838-3777 Kgolodetz@lhai.com or Bruce Voss 310-691-7100 Bvoss@lhai.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 0

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 0

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading